These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10836616)

  • 1. Can we predict flu-like symptoms in patients with multiple sclerosis treated with interferon-beta?
    Montalban X; Durán I; Río J; Sáez-Torres I; Tintoré M; Martínez-Cáceres EM
    J Neurol; 2000 Apr; 247(4):259-62. PubMed ID: 10836616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
    Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
    Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
    Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
    Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
    Jensen J; Krakauer M; Sellebjerg F
    Cytokine; 2005 Jan; 29(1):24-30. PubMed ID: 15579375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.
    Ozenci V; Kouwenhoven M; Huang YM; Kivisäkk P; Link H
    Clin Exp Immunol; 2000 Apr; 120(1):147-53. PubMed ID: 10759776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-beta1b for multiple sclerosis.
    Burks J
    Expert Rev Neurother; 2005 Mar; 5(2):153-64. PubMed ID: 15853486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.
    Río J; Nos C; Marzo ME; Tintoré M; Montalban X
    Neurology; 1998 Jun; 50(6):1910-2. PubMed ID: 9633761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
    Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS
    Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.
    Rudick RA; Ransohoff RM; Peppler R; VanderBrug Medendorp S; Lehmann P; Alam J
    Ann Neurol; 1996 Oct; 40(4):618-27. PubMed ID: 8871582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-β induces hepatocyte growth factor in monocytes of multiple sclerosis patients.
    Molnarfi N; Benkhoucha M; Bjarnadóttir K; Juillard C; Lalive PH
    PLoS One; 2012; 7(11):e49882. PubMed ID: 23166786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis.
    Dressel A; Kolb AK; Elitok E; Bitsch A; Bogumil T; Kitze B; Tumani H; Weber F
    Acta Neurol Scand; 2006 Dec; 114(6):368-73. PubMed ID: 17083335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreases in T-cell tumor necrosis factor alpha binding with interferon beta treatment in patients with multiple sclerosis.
    Bongioanni P; Mosti S; Moscato G; Lombardo F; Manildo C; Meucci G
    Arch Neurol; 1999 Jan; 56(1):71-8. PubMed ID: 9923763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction.
    Martínez-Cáceres EM; Río J; Barrau M; Durán I; Borrás C; Tintoré M; Montalban X
    Ann Neurol; 1998 Oct; 44(4):682-5. PubMed ID: 9778268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
    Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
    Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis.
    Kraus J; Bauer R; Chatzimanolis N; Engelhardt B; Tofighi J; Bregenzer T; Kuehne BS; Stolz E; Blaes F; Morgen K; Traupe H; Kaps M; Oschmann P
    J Neurol; 2004 Apr; 251(4):464-72. PubMed ID: 15083294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients.
    Bartosik-Psujek H; Stelmasiak Z
    Clin Neurol Neurosurg; 2006 Oct; 108(7):644-7. PubMed ID: 16343740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of interferon beta, cyclophosphamide and azathioprine on cytokine profile in patients with multiple sclerosis.
    Totaro R; Passacantando A; Russo T; Parzanese I; Rascente M; Marini C; Tonietti G; Carolei A
    Int J Immunopathol Pharmacol; 2005; 18(2):377-83. PubMed ID: 15888259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?
    Karp CL; van Boxel-Dezaire AH; Byrnes AA; Nagelkerken L
    Curr Opin Neurol; 2001 Jun; 14(3):361-8. PubMed ID: 11371761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS.
    Waubant E; Gee L; Bacchetti P; Sloan R; Cotleur A; Rudick R; Goodkin D
    J Neuroimmunol; 2001 Jan; 112(1-2):139-45. PubMed ID: 11108942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis.
    Wiesemann E; Deb M; Hemmer B; Radeke HH; Windhagen A
    Clin Immunol; 2008 Sep; 128(3):306-13. PubMed ID: 18539537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.